Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Briacell Therapeutics Corp

Healthcare US BCTX

3.31USD
0.04(1.22%)

Last update at 2026-06-03T20:00:00Z

Day Range

3.183.45
LowHigh

52 Week Range

3.6098.20
LowHigh

Fundamentals

  • Previous Close 3.27
  • Market Cap28.93M
  • Volume142904
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.63011M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-14.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -36.83398M -6.73886M -20.30239M -11.54996M 3.69M
Minority interest - 0.14M - - -
Net income -36.49516M -6.54744M -20.30239M -11.58069M -2.89464M
Selling general administrative 5.93M 0.00849M 7.94M 7.27M -3.67452M
Selling and marketing expenses - 0.00069M - - -
Gross profit -0.14789M -0.11464M - - -
Reconciled depreciation - 0.08M 0.02M 0.02M 0.02M
Ebit -36.78268M -6.73886M -22.38105M -15.28894M 3.69M
Ebitda -36.63479M -6.62422M -22.36578M -11.50298M 3.71M
Depreciation and amortization 0.15M 0.11M 0.02M 3.79M 0.02M
Non operating income net other - - - - -
Operating income -37.73369M -45.54488M -23.27226M -15.28894M 3.69M
Other operating expenses 37.73M 45.54M 23.27M -0.00339M -3.68978M
Interest expense 0.05M - 0.00000M 0.00098M 0.05M
Tax provision - - - - -
Interest income - 0.29M 0.89M 0.14M 0.00315M
Net interest income - 0.29M 0.89M -11.52262M -0.04295M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.06M - 0.03M 6.58M
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 37.59M 45.43M 23.27M -0.00339M -3.68978M
Cost of revenue 0.15M 0.11M - - -
Total other income expense net 0.90M 38.81M 2.08M 3.74M 6.58M
Discontinued operations - - - - -
Net income from continuing ops - -4.93155M -20.30239M -15.28894M -0.42833M
Net income applicable to common shares - - - -26.83890M -0.42833M
Preferred stock and other adjustments - - - - -
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 29.77M 5.87M 27.16M 42.58M 58.04M
Intangible assets 0.25M 0.20M 0.22M 0.23M 0.25M
Earning assets - - - - -
Other current assets 2.06M 1.42M 5.70M 1.31M 0.52M
Total liab 5.93M 8.56M 30.94M 32.25M 0.78M
Total stockholder equity 24.58M -2.38341M -3.77718M 10.33M 57.26M
Deferred long term liab - - - - -
Other current liab 0.95M 0.29M 0.68M 0.48M 0.56M
Common stock 139.88M 72.17M 69.59M 65.59M 54.78M
Capital stock - 72.17M 69.59M 65.59M 54.78M
Retained earnings -153.65421M -85.44370M -80.65223M -60.34984M -15.75403M
Other liab - - - 31.31M 0.20M
Good will - - - - -
Other assets - - - - -
Cash 14.43M 0.86M 21.25M 41.04M 57.27M
Cash and equivalents - - - - -
Total current liabilities 5.47M 7.46M 1.80M 0.94M 0.56M
Current deferred revenue - - - - -
Net debt -14.42807M -0.86209M -21.25109M -41.04165M -57.24270M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - 0.03M
Other stockholder equity 129.23M 11.03M 7.42M 5.23M 18.37M
Property plant equipment - - - - -
Total current assets 27.40M 3.65M 26.95M 42.35M 57.80M
Long term investments - 0.42M 0.00000M 0.00000M 0.00000M
Net tangible assets - - - 10.10M 57.02M
Short term investments 10.14M 0.00017M - - -
Net receivables 0.78M 1.37M 0.02M 0.02M 0.01M
Long term debt - - - - 0.03M
Inventory - -1.36959M -0.01887M -0.02410M -
Accounts payable 4.51M 7.17M 1.12M 0.46M 0.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 38.36M -0.13868M -0.13868M -0.13868M -0.13868M
Additional paid in capital - - - - -
Common stock total equity - - - 65.59M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -60.34984M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.99M 1.21M - - -
Deferred long term asset charges - - - - -
Non current assets total 2.37M 2.22M 0.22M 0.23M 0.25M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -0.68180M - - 0.00000M
Change to liabilities - - - 0.38M -2.19106M
Total cashflows from investing activities -10.60518M -0.93167M - - -
Net borrowings - - - - -0.33293M
Total cash from financing activities 63.04M 6.04M 3.95M -3.74266M 65.00M
Change to operating activities - - - -0.62893M -0.10098M
Net income -36.49516M -6.54744M -20.30239M -26.83890M -0.42833M
Change in cash 13.24M -28.23270M -19.79056M -16.22703M 57.25M
Begin period cash flow 1.19M 29.43M 41.04M 57.27M 0.02M
End period cash flow 14.43M 1.20M 21.25M 41.04M 57.27M
Total cash from operating activities -39.07316M -32.96787M -23.74486M -12.48438M -7.74765M
Issuance of capital stock - 4.42M 4.00M 0.00000M 51.62M
Depreciation 0.15M 0.11M 0.02M 0.02M 0.02M
Other cashflows from investing activities -0.33000M -0.00715M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 1.02M -1.00105M - -0.01153M 0.00994M
Sale purchase of stock - 0.00000M -0.04729M -10.17173M -
Other cashflows from financing activities -0.30323M -0.68180M 0.00159M 6.43M 13.92M
Change to netincome - - - 14.73M -5.05247M
Capital expenditures 0.00000M 0.62M 0.00000M 0.00000M 0.00000M
Change receivables - - - -0.01153M -
Cash flows other operating - - - -0.76646M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -16.22703M -
Change in working capital -2.64541M 9.64M -3.53200M -0.39129M -2.28211M
Stock based compensation 0.78M 1.80M 2.19M 3.07M 1.97M
Other non cash items -0.08047M -36.17341M -1.07259M 11.66M 1.84M
Free cash flow -39.07315M -33.59208M -23.74486M -12.48438M -7.74765M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BCTX
Briacell Therapeutics Corp		 0.04 1.22% 3.31 - - - 0.94 -1.3819
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Briacell Therapeutics Corp

Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1

Key Executives

Name Title Year Born
Dr. William V. Williams M.D. CEO, Pres & Director 1956
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA CFO & Corp. Sec. 1973
Dr. Miguel A. Lopez-Lago Chief Scientific Officer 1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPH Chief Medical Officer 1962
Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Research Advisor & Member of Scientific Advisory Board 1946
Dr. William V. Williams M.D. CEO, President & Director 1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CFO & Corporate Secretary 1973
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer 1969
Dr. William V. Williams FCPA, M.D. CEO, President & Director 1955
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.